scholarly journals Impact of antiviral prophylaxis in adults Epstein-Barr Virus-seronegative kidney recipients on early and late post-transplantation lymphoproliferative disorder onset: a retrospective cohort study

2018 ◽  
Vol 31 (5) ◽  
pp. 484-494 ◽  
Author(s):  
Simon Ville ◽  
Berthe-Marie Imbert-Marcille ◽  
Marianne Coste-Burel ◽  
Claire Garandeau ◽  
Aurélie Meurette ◽  
...  
Keyword(s):  
Cohort Study ◽  
Retrospective Cohort Study ◽  
Retrospective Cohort ◽  
Lymphoproliferative Disorder ◽  
Epstein Barr Virus ◽  
Antiviral Prophylaxis ◽  
Post Transplantation ◽  
Barr Virus ◽  
Kidney Recipients ◽  
Epstein Barr

scholarly journals Evaluation of Epstein-Barr Virus Salivary Shedding in HIV/AIDS Patients and HAART Use: A Retrospective Cohort Study

2018 ◽  
Vol 33 (3) ◽  
pp. 227-233 ◽  
Author(s):  
Yan Yan ◽  
Yong Ren ◽  
Renfang Chen ◽  
Jing Hu ◽  
Yongjia Ji ◽  
...  
Keyword(s):  
Cohort Study ◽  
Retrospective Cohort Study ◽  
Retrospective Cohort ◽  
Epstein Barr Virus ◽  
Aids Patients ◽  
Barr Virus ◽  
Epstein Barr ◽  
Hiv Aids

scholarly journals Early Gastric Post-Transplant Lymphoproliferative Disorder andH pyloriDetection after Kidney Transplantation: A Case Report and Review of the Literature

2000 ◽  
Vol 14 (8) ◽  
pp. 721-724 ◽  
Author(s):  
CL Nash ◽  
LM Price ◽  
DA Stewart ◽  
F Sepandj ◽  
S Yilmaz ◽  
...  
Keyword(s):  
Renal Transplantation ◽  
Lymphoproliferative Disorder ◽  
Epstein Barr Virus ◽  
Antibody Therapy ◽  
Treatment Modalities ◽  
Review Of The Literature ◽  
Post Transplantation ◽  
Barr Virus ◽  
Epstein Barr ◽  
H Pylori

The incidence of post-transplantation lymphoproliferative disorder (PTLD) in the adult renal transplant population ranges from 0.7% to 4%. The majority of cases involve a single site and arise, on average, seven months after transplantation. Histopathology usually reveals B-cell proliferative disease and has been standardized into its own classification. Treatment modalities consist of decreased immunosuppression, eradication of Epstein-Barr virus, surgical resection, systemic chemotherapy and monoclonal antibody therapy; however, mortality remains high, typically with a short survival time. In patients who have undergone renal transplantation, approximately 10% of those with PTLDs present with gastrointestinal symptomatology and disease. Reported sites include the stomach, and small and large bowel. Very few cases ofHelicobacter pylorior mucosal-associated lymphoid tissue have been described in association with PTLD. In the era of cyclosporine immunosuppression, the incidence of PTLD affecting the gastrointestinal tract may be increasing in comparison with the incidence seen with the use of older immunosuppression regimens. A case of antral PTLD andH pyloriinfection occurring three months after renal transplantation is presented, and the natural history and management of gastric PTLD are reviewed.

Sign in / Sign up

Export Citation Format

Share Document